Prosensa Closes $30M Round for Exon-Skipping Drug Pipeline
BioWorld Today Correspondent
Prosensa Therapeutics BV raised €23 million (US$29.9 million) in a Series C round to enable it to move two new exon-skipping antisense oligonucleotide drugs into clinical development in Duchenne's muscular dystrophy (DMD) and to take forward preclinical programs in two other rare disease indications.
Outside of the US
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST